Tolerogenic insulin peptide therapy precipitates type 1 diabetes

Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified ins...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of experimental medicine 2017-07, Vol.214 (7), p.2153-2156
Main Authors: Bergman, Marie-Louise, Lopes-Carvalho, Thiago, Martins, Ana-Catarina, Grieco, Fabio A, Eizirik, Décio L, Demengeot, Jocelyne
Format: Article
Language:English
Subjects:
Animals
Autoantibodies - blood
Autoantibodies - immunology
Diabetes
Diabetes mellitus
Diabetes Mellitus, Type 1 - blood
Diabetes Mellitus, Type 1 - immunology
Diabetes Mellitus, Type 1 - prevention & control
Epitopes - immunology
Female
Humans
Hyperglycemia
Hyperglycemia - immunology
Hyperglycemia - prevention & control
Immunization
Insulin
Insulin - immunology
Insulin Antibodies - blood
Insulin Antibodies - immunology
Insulitis
Letter
Mice, Inbred NOD
Microscopy, Fluorescence
Precipitates
Vaccination
Vaccination - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Daniel et al. (https://doi.org/10.1084/jem.20110574) have previously published in JEM a study on the preventive effect of tolerogenic vaccination with a strong agonist insulin mimetope in type 1 diabetes. Our study now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R22E did not prevent hyperglycemia, accelerated disease onset, increased its incidence, and worsened insulitis.
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20160471